Minnesota is currently home to 2063 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
Recruiting
The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to continue dosing for the potential treatment of their condition.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
11/26/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Gene Mutations, Pseudoxanthoma Elasticum, Arterial Calcification, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets Type 2
Daratumumab in Primary Antiphospholipid Syndrome
Recruiting
The purpose of this study is to see if the study medication, daratumumab, is safe to treat individuals with Anti-Phospholipid Syndrome (APS). Three daratumumab dosing cohorts are planned with up to six participants in each dosing cohort with the potential to enroll an additional 4 subjects in the highest safe dose (HSD) cohort, for a total of up to 22 participants. The dosing cohorts are: 4 mg/kg, 8 mg/kg, and 16 mg/kg. Each cohort will receive intravenous (IV) administration of daratumumab acc... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/26/2024
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Autoimmune Disorders
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
Recruiting
The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/25/2024
Locations: Clinical Trial Site, Minneapolis, Minnesota
Conditions: Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
Recruiting
The overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline in memory, thinking and other mental abilities that significantly affects daily functioning) after their stroke so that future treatments may be developed to improve outcomes in stroke patients. For this study, a "stroke... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: University of Minnesota Health, Minneapolis, Minnesota
Conditions: Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Dementia, Vascular, Mild Cognitive Impairment, Vascular Cognitive Impairment
Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures At High Risk of Infection: TOBRA
Recruiting
The overall objective is to compare the effect of Vancomycin and Tobramycin powder combined (treatment) to Vancomycin powder (control) in the reduction of post-fixation infections of tibial plateau and tibial pilon fractures at high risk of infection (collectively considered the "study injuries").
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/25/2024
Locations: Hennepin County Medical Center, Minneapolis, Minnesota
Conditions: Post Operative Surgical Site Infection
ProACT Post-Approval Study
Recruiting
The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and device erosion after ProACT implantation. In addition, the study will evaluate whether treatment with ProACT affects clinical outcomes after subsequent SUI therapies.
Gender:
MALE
Ages:
50 years and above
Trial Updated:
11/25/2024
Locations: CentraCare- St. Cloud, Saint Cloud, Minnesota
Conditions: Stress Urinary Incontinence
Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
Recruiting
This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in treating patients with hormone sensitive prostate cancer that has spread from where it first started to other places in the body (metastatic), and that has come back after a period of improvement (recurrent). SBRT is a type of external radiation therapy that uses special equipment to position a... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Recurrent Castration-Sensitive Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer
Identification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters
Recruiting
This study is being done to identify and differentiate thyroid nodules by acoustic imaging and viscoelastic parameters.
Gender:
ALL
Ages:
8 years and above
Trial Updated:
11/22/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Thyroid Gland Carcinoma
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Recruiting
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Research Site, Saint Paul, Minnesota
Conditions: Breast Cancer
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
Recruiting
This clinical trial evaluates the use of cytosponge, a minimally invasive collection device, for the detection of Barrett's esophagus (BE) in patients undergoing endoscopy. Non-endoscopic swallowable encapsulate sponge cell collection devices combined with markers for BE/esophageal adenocarcinoma (EAC) detection are a guideline-endorsed alternative to endoscopy for BE screening. The Oncoguard registered trademark Esophagus test (OGE) test uses esophageal cytology specimens collected with a minim... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
11/22/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Barrett Esophagus, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia, Esophageal Adenocarcinoma
NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis
Recruiting
The Researchers are trying to compare two different types of intraarticular injections (injection in the joint) for treating the symptoms of moderate to advanced basilar thumb arthritis. One injection is ketorolac (an NSAID) and the other is triamcinolone (a corticosteroid).
Gender:
ALL
Ages:
40 years and above
Trial Updated:
11/22/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Thumb Osteoarthritis
Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)
Recruiting
The purpose of this Phase 2, open-label, sequential dose cohort study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of CRN04894 in participants with classic congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency.
Gender:
ALL
Ages:
Between 16 years and 75 years
Trial Updated:
11/22/2024
Locations: Crinetics Study Site, Minneapolis, Minnesota
Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia